Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / ARQT - Arcutis launches plaque psoriasis therapy Zoryve in US


ARQT - Arcutis launches plaque psoriasis therapy Zoryve in US

  • Arcutis Biotherapeutics ( NASDAQ: ARQT ) said it launched its plaque psoriasis cream Zoryve in the U.S.
  • In July, the U.S. FDA approved Zoryve (roflumilast) cream 0.3% for topical use to treat plaque psoriasis in people aged 12 years and older.
  • The company said the product was available via ZORYVE Direct pharmacies — contracted pharmacy partners that help commercially insured individuals get access to the drug — and will be available for ordering at pharmacies nationwide no later than Aug. 15.

For further details see:

Arcutis launches plaque psoriasis therapy Zoryve in US
Stock Information

Company Name: Arcutis Biotherapeutics Inc.
Stock Symbol: ARQT
Market: NASDAQ
Website: arcutis.com

Menu

ARQT ARQT Quote ARQT Short ARQT News ARQT Articles ARQT Message Board
Get ARQT Alerts

News, Short Squeeze, Breakout and More Instantly...